Advertisements

Cisordinol

Quick links to important sections

Cisordinol

Selected form

Advertisements
Advertisements

Treatment option: Schizophrenia

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Cisordinol

Quick Facts

Property Description
Active ingredient Zuclopenthixol
Form Tablets, Solution for injection, Depot injection
Pharmacological class First-Generation Antipsychotic (FGA) / Neuroleptic
Common use Managing severe mental disturbances
Origin Synthetic, Thioxanthene derivative

What Type of Medicine is Cisordinol?

Cisordinol is a synthetic pharmaceutical whose active component is Zuclopenthixol, officially categorized as a First-Generation Antipsychotic (FGA), commonly referred to as a typical neuroleptic agent. It operates exclusively as a prescription-only medicine (POM) intended to provide a comprehensive psychotropic action to stabilize severe mental disturbances. The compound belongs to the distinct chemical group of thioxanthene derivatives, differentiating it from other antipsychotics such as phenothiazines or butyrophenones. This specific chemical architecture is what confers its potency and makes it a specialized agent used to exert strong, regulating effects on the central nervous system.


Composition and Available Forms of Zuclopenthixol

The active ingredient, Zuclopenthixol, is prepared in three primary delivery forms to suit different needs: film-coated tablets for standard oral use, a short-acting solution for injection for immediate support, and a depot injection for parenteral (intramuscular) administration. The availability of the depot injection utilizing the ester Zuclopenthixol decanoate is a key feature; this long-acting injectable (LAI) formulation is dissolved in an oily vehicle (such as fractionated coconut oil) to allow a controlled, gradual release of the active drug over an extended period. This system provides sustained drug levels, which can be particularly useful in maintaining consistent treatment compliance.


General Purpose: Stabilizing Mental State

The overarching purpose of Cisordinol is to restore a more balanced chemical environment in the brain, thereby promoting stability and controlling mental overactivity. This is primarily achieved through its core action of dopamine receptor blockade, where the drug helps regulate the activity of the neurotransmitter dopamine. By dampening mental overactivity and providing a notable sedative effect, this medication assists in quieting disruptive thoughts and behaviors, offering support in achieving and maintaining overall emotional and behavioral composure.

Advertisements

What side effects are possible with Cisordinol?

Possible Side Effects and Safety Information

The safety profile of Zuclopenthixol (Cisordinol) is formally documented in regulatory sources, classifying possible adverse reactions by frequency and the body system affected. These classifications establish the expected risk profile without containing any instructions for use or clinical advice.

Commonly Observed Reactions

The most frequently reported adverse reactions are often related to the Nervous system, categorized as Very Common or Common. These include somnolence (sleepiness) and akathisia (a feeling of inner restlessness and need to move), as well as various other forms of altered movement control (extrapyramidal symptoms), dizziness, and headache. Gastrointestinal effects like xerostomia (dry mouth) and constipation, along with weight gain and fatigue, are also commonly listed.

Serious Adverse Reactions and Constraints

Official regulatory information highlights the potential for serious, yet infrequent, events. These include the risk of Neuroleptic Malignant Syndrome (NMS), a rare but severe reaction characterized by high fever and muscle rigidity. The label also notes the association of antipsychotics with Venous Thromboembolism (VTE) and the potential for QT prolongation, a serious cardiac effect.

Use of the medicine is contraindicated in cases of circulatory collapse or a depressed level of consciousness (e.g., due to intoxication).

Safety Considerations for Specific Groups

The official labeling specifies that older patients require particular caution due to increased risk of effects like sedation and confusion. Dosage adjustments are formally recommended for patients with hepatic impairment (reduced liver function). Furthermore, the regulatory documents contain explicit safety statements regarding exposure during the third trimester of pregnancy, noting the risk of extrapyramidal or withdrawal symptoms in the neonate. Certain effects, such as sedation and initial movement changes, are officially noted as being most prominent at the start of treatment.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Zuclopenthixol (Cisordinol) defines overdose as a severe and potentially life-threatening event. The documented overdose profile primarily involves central nervous system (CNS) and cardiovascular system effects.

Documented Overdose Manifestations

System Manifestations Listed in Labeling
Central Nervous System Somnolence, depressed consciousness progressing to coma, severe extrapyramidal symptoms (EPS), and convulsions.
Cardiovascular System Hypotension, tachycardia, and potentially dangerous QT interval prolongation on the ECG, leading to a risk of shock.

Required Emergency Actions

The regulatory guidance is explicit that immediate medical attention must be sought for any suspected overdose. Emergency services should be contacted if the person exhibits signs of collapse, unconsciousness, severe hypotension, or irregular heartbeat. Treatment is strictly symptomatic and supportive; no specific antidote is known for Zuclopenthixol overdose.

Management procedures described in official documents include continuous hospital monitoring of cardiovascular function and consideration of gastric lavage or administration of activated charcoal to limit further absorption.

Advertisements

Therapeutic Uses of Cisordinol

Cisordinol is commonly used across conditions presenting with acute episodes and applied across domains where additional symptomatic support is needed for severe mental health conditions. The medication is indicated for the management of the manifestations of schizophrenia and is considered relevant for the initial treatment of acute psychotic episodes.

It is used to help address symptom clusters that may become intense or disruptive, such as hallucinations, delusions, thought disturbances, agitation, and restlessness. Applicable in conditions involving episodic or fluctuating manifestations, Cisordinol offers symptomatic relief that helps patients cope more steadily with difficult episodes, supporting the patient in maintaining a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Acute Distress Cisordinol provides support that helps ease the overall symptom burden in situations involving acute or unstable symptom patterns, contributing to improved comfort during periods of heightened symptoms.

Regulatory References

  1. Health Canada Product Monograph for Clopixol
Advertisements

Eligibility and Restrictions for Use

Eligibility for Cisordinol (Zuclopenthixol) is defined by regulatory authorities based on a patient's age, physiological status, and underlying health conditions.


Populations Permitted and Restricted

Cisordinol is established for use primarily in adults (18 years and older) for labeled psychiatric conditions. Conversely, use in children and adolescents (under 18) is not recommended because safety and efficacy in this age group have not been established [UK SmPC].

Older adults (geriatric patients) can be eligible for treatment, but their use is conditional, often requiring a reduced starting dosage [UK SmPC].


Absolute Contraindications

Cisordinol must not be used in patients with absolute contraindications defined by official labeling:

  • Hypersensitivity to Zuclopenthixol or any other medicine belonging to the thioxanthene class.
  • Central Nervous System (CNS) Depression, including patients in a comatose state or those suffering from acute intoxication with alcohol, barbiturates, or opioids.
  • Circulatory collapse or suspected subcortical brain damage.

Use Restrictions

Conditional use is required for patients with certain medical conditions:

  • Hepatic Impairment: Use requires caution, and a lower starting dose is recommended in severe liver disease.
  • Renal Impairment: Use is generally acceptable in typical doses but should be reduced to half the normal dosage in cases of renal failure.
  • Pregnancy and Lactation: Use is not recommended during pregnancy unless the benefit clearly justifies the risk. The medicine is also not recommended for women who are breastfeeding.
Advertisements

What should I know about interactions with other medicines?

Cisordinol Interactions with other medicines and products

Cisordinol (zuclopenthixol) has documented interactions with several classes of medicines, potentially affecting its efficacy or increasing the risk of adverse effects. These interactions are categorized as follows:


Interactions Resulting in Potentiation of Effects

Interacting Product Category Effect/Clinical Concern
Central Nervous System (CNS) Depressants (e.g., alcohol, general anaesthetics, barbiturates, hypnotics) Enhanced sedative effect and CNS depression. Acute alcohol intoxication is a contraindication.
CYP2D6 Inhibitors (e.g., specific antidepressants) Decreased clearance of zuclopenthixol, potentially increasing its concentration and effects.
Medicinal products that prolong the QT interval (e.g., certain anti-arrhythmics) Increased risk of serious heart rhythm disorders; co-administration must be avoided.

Interactions Resulting in Antagonism or Increased Risk

Interacting Product Category Effect/Clinical Concern
Dopaminergic agents (e.g., levodopa) Cisordinol may reduce the therapeutic effect of these agents.
Adrenergic drugs and Antihypertensives (e.g., guanethidine) Cisordinol may reduce their effect, potentially lowering blood pressure control.
Metoclopramide and Piperazine Increased risk of extrapyramidal movement disorders.
Lithium Increased risk of neurotoxicity.
Agents affecting platelet function (e.g., oral anticoagulants like warfarin, NSAIDs, acetylsalicylic acid) Caution is advised due to potential bleeding risk.
Advertisements

Mechanism of Action

Dopaminergic Pathway Modulation

Cisordinol (zuclopenthixol) primarily acts as an antagonist within the central nervous system, exhibiting high affinity for dopamine receptors, specifically the D1 and D2 subtypes. This receptor blockade limits the influence of dopamine-mediated signaling in key neural pathways. The resulting mechanistic consequence is the modulation of neural signaling intensity due to reduced post-synaptic receptor activation, affecting cellular processes sensitive to these neurochemical inputs.


Serotonin and Adrenergic Receptor Engagement

Beyond its primary interaction, the compound engages other signaling targets, possessing affinity for alpha-1 adrenergic receptors and 5-HT2 serotonin receptors. Its antagonistic action at these sites contributes to a modification of early molecular steps within norepinephrine- and serotonin-regulated cascades. This multi-receptor profile induces changes in neurophysiological response patterns by limiting receptor-mediated input, influencing pathways sensitive to concurrent monoamine antagonism.

Advertisements

Dosage and Administration Information

How to Use Cisordinol (Zuclopenthixol)

Cisordinol is administered through three distinct formulations, each following specific regulatory rules regarding its route, dose, and frequency to manage different phases of treatment. The medicine is available as oral tablets (Zuclopenthixol dihydrochloride), a short-acting solution for injection (Zuclopenthixol acetate), and a long-acting Depot injection (Zuclopenthixol decanoate).


Administration and Dosing Patterns

The oral tablets are swallowed whole with water and may be taken irrespective of food. The total daily dose is typically administered in divided doses, though maintenance may involve a single dose at bedtime. Standard adult initial dosing often starts at 20–30 mg per day, with maintenance ranging from 20–50 mg per day, up to a maximum daily dose of 150 mg.

Both injectable solutions require administration via deep intramuscular (IM) injection by a trained healthcare professional. The short-acting injection is intended for time-limited use only, with repeat doses given at intervals of two to three days, and the total course duration should not exceed two weeks.

For long-term use, the Depot injection is administered IM at intervals of every two to four weeks. When converting a patient from oral tablets to the Depot injection, the oral medication must be gradually withdrawn over several days following the initial Depot dose.


Population-Specific Adjustments

Official guidelines require specific dosage modifications for certain patient populations. For older adults and individuals with hepatic impairment, a dose reduction is usually necessary, often beginning at the lower end of the recommended range. Use in the pediatric population is not recommended due to insufficient data.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cisordinol


Research Evidence for the Management of Schizophrenia (Oral Formulations)

Research examined how oral Zuclopenthixol was applied for conditions characterized by fluctuating or episodic manifestations, such as schizophrenia. The evidence base primarily consists of short-term Randomized Controlled Trials (RCTs) and systematic reviews where the oral form of Cisordinol was studied. These studies research examined how symptoms are measured over time in adult patients and monitored outcomes related to systemic or functional imbalance, including changes in global clinical state and specific psychotic symptom scores.

Findings describe patterns observed in the studies over the defined time intervals, typically lasting only a few weeks to three months. Studies report how symptoms evolved in the observed populations and monitored the proportion of participants who discontinued the trial prematurely. Evidence quality varies across studies, and many of the trials are older, meaning the data available for synthesis may be limited and heterogeneous.


Evidence for Acute Management of Severe Agitation (Short-Acting Injection)

The short-acting injectable form was studied for its use during conditions associated with acute or disruptive episodes, such as periods of severe agitation or aggression linked to psychosis. This research involved very short-term Randomized Controlled Trials (RCTs), often comparing the injection to other short-acting treatments in the acute setting. These studies research examined acutely disturbed adult inpatients, and research explored specific outcomes describing episodic or acute changes. Key measurements included the degree of sedation achieved within hours of administration and the subsequent need for supplementary injections.

Evidence is limited for outcomes related to broader patient experience, and data for the outcome of tranquilization was often not reported in the scientific summaries. Follow-up durations were limited, typically covering only a few hours up to one week, offering limited insight into the full duration of the acute episode or subsequent management.


Research on Maintenance and Relapse Prevention (Depot Injection)

The depot, or long-acting injectable (LAI) formulation, was evaluated in studies focusing on conditions presenting with cycles of stability and flare-ups, specifically maintenance treatment for schizophrenia. This research primarily involved Randomized Controlled Trials (RCTs) that compared the depot injection against other long-acting medications. The trials research explored outcomes, including the time until relapse and monitored the overall rates of discontinuation from the study.

Long-term effects are not fully established because trial durations were frequently short-term relative to the extended period relevant to maintenance evaluation. Limited information for long-term outcomes is available regarding patient-reported experiences or costs related to ongoing care. Additionally, comparative evidence is lacking for the depot form versus a non-active treatment control (placebo), as most research compared it to other active long-acting treatments.

Key Studies & References

  1. Health Canada Product Monograph for Clopixol
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Cisordinol (FAQ)

Q: How quickly should someone notice Cisordinol starting to work?

A: Official information indicates that the short-acting injection is intended for rapid action in acute, severe situations, with effects potentially noticeable within hours. However, when taking oral tablets for maintenance treatment, achieving the full potential for symptom control may take an extended period, which official sources indicate can span several months.

Q: Can Cisordinol affect sleep patterns or cause drowsiness?

A: Regulatory documents indicate potential effects related to sleep. Somnolence, which is the medical term for sleepiness or drowsiness, is listed as a very common adverse reaction. Conversely, insomnia, which is difficulty sleeping, is also listed as a common reaction.

Q: Is it necessary to avoid alcohol completely while taking Cisordinol?

A: Official labeling states that co-administration with central nervous system (CNS) depressants like alcohol can cause enhanced sedation. The medicine is formally described as unsuitable for use in individuals with acute alcohol intoxication.

Q: Can people who drive still use Cisordinol?

A: The medicine is officially described as being sedative. Regulatory warnings caution that psychotropic medication may cause some impairment in general attention and concentration. This potential for impairment is mentioned in the official labeling as relevant to performing skilled tasks such as driving or operating machinery.

Q: What are the official sources of information about Cisordinol?

A: Authoritative medical facts about the drug are formally documented and regulated by governmental bodies worldwide. These sources include the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC), the UK Medicines and Healthcare products Regulatory Agency (MHRA), and Health Canada regulatory documents.

Q: How often is Cisordinol usually taken?

A: The frequency depends on the formulation being used. Oral tablets are typically administered in divided doses daily, but official prescribing information notes that maintenance may involve a single dose taken at bedtime. The long-acting injection (Depot) is administered much less frequently, usually at intervals of every two to four weeks.

Q: What happens if a dose of Cisordinol is missed?

A: Official patient information notes that if an oral tablet dose is missed, it should be taken at the next scheduled time, and doses are not to be doubled to make up for the missed dose. For the long-acting injection, the dose should be administered as soon as possible by a professional, and the usual dosing interval will then follow from that date.

Q: Is Cisordinol a 'first-line' treatment for certain conditions?

A: The regulatory indications state the medicine's use for conditions such as acute psychosis, mania, or the worsening of long-term psychosis, as well as for maintenance treatment in schizophrenia. The regulatory text defines its role for both acute and maintenance treatment for severe mental disturbances, which establishes its position within the overall treatment strategy.

Q: Does Cisordinol interact with common over-the-counter pain relievers?

A: Official documentation notes that co-administration with agents that affect platelet function requires careful monitoring. This includes non-steroidal anti-inflammatory drugs (NSAIDs) and acetylsalicylic acid (aspirin), due to a potential increased risk of bleeding.

Q: What kind of monitoring or tests might be required while taking Cisordinol?

A: Because the drug may modify how the body processes blood sugar, official information notes that monitoring of blood glucose levels is a consideration. Furthermore, due to the potential for a serious cardiac effect called QT prolongation, careful monitoring related to heart rhythm is mentioned for susceptible individuals.

Q: Can Cisordinol be used by people with a history of heart issues?

A: Regulatory documents state that Cisordinol should be used with caution in individuals who have a history of cardiovascular disorders. This includes people with significant bradycardia (slow heart rate), congenital long QT syndrome, or who have recently experienced an acute myocardial infarction (heart attack).

Q: Are the side effects of Cisordinol permanent or do they usually go away?

A: Official safety documents describe several adverse effects as reversible upon discontinuation of the medicine. However, official information warns of the potential, though rare, risk of developing a serious movement disorder called Tardive Dyskinesia (TD), which is considered potentially irreversible.

Q: Can Cisordinol cause dizziness or problems with balance?

A: Yes, dizziness is listed as a common adverse reaction in the official safety documents. Additionally, 'abnormal gait,' which refers to problems with walking or balance, is also listed as a common adverse reaction.

Q: Is it true that Cisordinol can affect blood sugar levels?

A: Regulatory information notes that Cisordinol may modify how the body handles insulin and glucose. Hyperglycaemia (high blood sugar) and impaired glucose tolerance are listed as rare adverse reactions.

Q: What should be done if someone experiences severe or unusual side effects from Cisordinol?

A: Official patient information advises seeking immediate medical help for serious events such as symptoms resembling Neuroleptic Malignant Syndrome (NMS), high fever, or severe muscle stiffness. Official instructions note that any severe or unusual side effect warrants consultation with a healthcare professional.

Q: Can Cisordinol affect a person's mood or personality beyond its intended effects?

A: Yes, official safety documents list several psychiatric effects beyond the therapeutic action. Both depression and anxiety are listed as common adverse reactions. Uncommon reactions listed include apathy and a confusional state.

Q: Are there genetic factors that influence how Cisordinol works for a person?

A: Official regulatory information notes that the drug is partly processed by an enzyme called CYP2D6. Genetic differences in this enzyme can potentially affect how quickly the drug is cleared from the body. Individuals with a genetic predisposition to certain electrolyte imbalances are also noted in relation to heart rhythm risk.

Q: How does the time of day someone takes Cisordinol affect them?

A: Since the medicine can cause drowsiness, official dosing information states that while oral tablets are typically given in divided doses throughout the day, the maintenance dose may sometimes be administered as a single dose taken at bedtime. This indicates that the option for a single dose at bedtime is related to the sedative properties of the medication.

Q: Are there any long-term health risks associated with Cisordinol use, according to official data?

A: Yes, official warnings describe a risk of developing Venous Thromboembolism (VTE), which are blood clots, and the potential for a serious heart rhythm issue called QT prolongation. There is also the potential for a movement disorder called Tardive Dyskinesia (TD) which can be permanent with long-term use.

Q: What are common user experiences with the 'tiredness' side effect of Cisordinol?

A: Official frequency classifications derived from regulatory studies indicate that both fatigue and somnolence (sleepiness) are described as common to very common adverse reactions. These classifications represent the frequency of reports collected in clinical trials.

Q: Can Cisordinol affect the liver or kidney function?

A: The need for dosage adjustments is formally recognized for patients who have pre-existing hepatic impairment (reduced liver function) or renal failure (kidney function). This indicates that the body's processing of the drug is dependent on these organs, and caution is needed in these populations.

Q: What evidence exists about using Cisordinol during pregnancy or breastfeeding?

A: Official labeling advises that use is not recommended during pregnancy unless the potential benefit clearly justifies the risk, due to the observed risk of extrapyramidal or withdrawal symptoms in the newborn. Low levels are found in breast milk, and official information notes that while it is not likely to affect the infant, the decision requires careful clinical consideration.

Q: Does Cisordinol have different effects on men and women?

A: Official adverse event lists include effects that are sex-specific. Examples include erectile dysfunction and ejaculation failure listed for men, and amenorrhoea (missed menstrual periods) and galactorrhoea (milk discharge) listed for women.

Q: Can people with low blood pressure safely take Cisordinol?

A: Because hypotension (low blood pressure) is listed as an uncommon adverse reaction, and the drug interacts with agents that control blood pressure, the potential for low blood pressure as an adverse reaction indicates that use in individuals with pre-existing low blood pressure requires clinical caution.

Advertisements

How should Cisordinol be stored and disposed of?

How to Store and Dispose of Cisordinol?

The storage and disposal instructions for Cisordinol (zuclopenthixol) are determined by the regulatory requirements for pharmaceutical safety and stability.


Storage Conditions

Requirement Specific Instruction
Temperature No special temperature storage conditions are required for the 10 mg and 25 mg film-coated tablets.
Light Protection The 2 mg film-coated tablets must be stored in the original container to protect from light.
Child Safety All forms of the medicine must be kept out of the sight and reach of children.

Disposal Instructions

Any unused medicinal product or waste material must be disposed of in accordance with local requirements. This instruction mandates following established pharmaceutical waste procedures, such as a medicine take-back program, rather than discarding the product in household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cisordinol found in:

A-Z Index: